Bluejay net loss widens to $2.32 million in Q2 FY26 - BJDX News | RalliesBluejay net loss widens to $2.32 million in Q2 FY26
B
BJDX• Quarterly results and cash position
- Bluejay Diagnostics posted a net loss of USD 2.32 million for the quarter ended June 30, 2026, widening from USD 1.96 million.
- Operating loss widened to USD 2.35 million from USD 1.99 million, as operating expenses rose to USD 2.35 million.
- Research and development expense climbed to USD 1.44 million from USD 889,896, driven by higher clinical development costs.
- General and administrative expense fell to USD 911,318 from USD 1.1 million on lower legal and accounting fees.
- Cash and cash equivalents totaled USD 9.6 million at June 30, 2026; cash runway seen through the second quarter of 2027.
AEP
•
